Halozyme Therapeutics Inc (NASDAQ:HALO)
| 33.59 Delayed Data As of Jun 02 |  +1.10 / +3.39%Today’s Change | 29.85 Today|||52-Week Range 59.46 | -40.97% Year-to-Date |
Latest HALO News | Press Releases
| Are You a Value Investor? This 1 Stock Could Be the Perfect Pick May 25 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 32.49 |
| Today’s open | 32.60 |
| Day’s range | 32.60 - 33.59 |
| Volume | 23,535 |
| Average volume (3 months) | 1,436,706 |
| Market cap | $4.4B |
Data as of 3:59pm ET, 06/02/2023
Growth & Valuation
| Earnings growth (last year) | -48.41% |
| Earnings growth (this year) | +72.53% |
| Earnings growth (next 5 years) | +26.00% |
| Revenue growth (last year) | +48.91% |
| P/E ratio | 26.3 |
| Price/Sales | 12.12 |
| Price/Book | 26.43 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| DNLIDenali Therapeutics ... | +0.52 | +1.68% |
| ---- | ||
| ---- | ||
| ARWRArrowhead Pharmaceut... | +1.39 | +4.01% |
Data as of 4:00pm ET, 06/02/2023
Financials
| Next reporting date | August 8, 2023 |
| EPS forecast (this quarter) | $0.60 |
| Annual revenue (last year) | $660.1M |
| Annual profit (last year) | $202.1M |
| Net profit margin | 30.62% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
